Table 1.

General characteristics of premenopausal women with PDM who received either vitamin K1 supplements or placebo

	Placebo group (n = 43)	Phylloquinone group (n = 39)	P value
Age (y)	40.09 ± 4.65	40.25 ± 5.32	0.88*
Weight (kg) at study baseline	71.09 ± 6.59	71.21 ± 6.47	0.93*
Weight (kg) at end of trial	71 ± 6.76	70.72 ± 6.39	0.84*
BMI (18.5-24.9 kg/m2) at study baseline	1(2.3%)	3(7.7%)	0.342**
BMI (18.5-24.9 kg/m2) at the end of trial	2(4.7%)	5(12.8%)	0.249**
BMI (25–29.9 kg/m2) ) at study baseline	42(97.7%)	36(92.3%)	0.342**
BMI (25–29.9 kg/m2) at the end of trial	41(95.3%)	34(87.2%)	0.249**
FM (%) at study baseline	38.55 ± 3.99	38.77 ± 3.86	0.79*
FM (%) at end of trial	38.57 ± 4.10	38.46 ± 4.05	0.90*
HbA1C (%) at study baseline	5.91 ± 0.49	5.81 ± 0.64	0.42*

All values are means ± SDs.

*Obtained from independent-samples t test.

**Obtained from chi-square test.